Study Feasibility and Site Selection

Role of Enrollment Timelines in Performance Review

Posted on digi By digi

Enrollment timelines are a pivotal component in determining the overall performance of clinical trial sites. A site’s ability to recruit participants on schedule not only affects trial duration and resource utilization but also signals its operational maturity, investigator engagement, and infrastructure capability. Regulatory authorities such as the FDA and EMA expect sponsors to make data-driven site selection decisions, and past enrollment performance is one of the most objective and predictive indicators available.
Click to read the full article.

Historical Performance Review, Study Feasibility and Site Selection

Assessing Protocol Deviations in Past Trials

Posted on digi By digi

Protocol deviations (PDs) are critical indicators of a clinical trial site’s operational discipline, training adequacy, and regulatory compliance. Reviewing historical deviation patterns across a site’s prior trials enables sponsors and CROs to predict future risks, evaluate data integrity, and identify sites needing additional oversight or requalification.
Click to read the full article.

Historical Performance Review, Study Feasibility and Site Selection

Benchmarking Site Performance Across Studies

Posted on digi By digi

Clinical trial sponsors and CROs often engage sites repeatedly across multiple protocols and therapeutic areas. Yet, not all site performances are equal—some consistently exceed expectations while others underperform. Benchmarking site performance across studies enables feasibility teams to identify high-value partners, optimize site portfolios, and reduce trial risk through objective data-driven selection.
Click to read the full article.

Historical Performance Review, Study Feasibility and Site Selection

Lessons from Underperforming Sites

Posted on digi By digi

While much attention is given to high-performing clinical trial sites, underperforming sites hold equally valuable insights. Whether it’s delays in startup, failure to enroll, data quality issues, or protocol non-compliance, these sites represent high-risk nodes that impact trial timelines, regulatory confidence, and overall study cost. Reviewing lessons from past site underperformance is critical for enhancing feasibility planning, refining site selection SOPs, and building future-ready oversight systems.
Click to read the full article.

Historical Performance Review, Study Feasibility and Site Selection

Performance Scorecards for Investigator Sites

Posted on digi By digi

In an era of data-driven decision-making, investigator site selection can no longer rely solely on subjective reputation or ad hoc feasibility questionnaires. Sponsors and CROs now leverage performance scorecards—quantitative tools that aggregate site metrics across past trials—to ensure high-quality, compliant, and efficient clinical trial execution.
Click to read the full article.

Historical Performance Review, Study Feasibility and Site Selection

Link Between Performance and Regulatory Compliance

Posted on digi By digi

When a clinical trial site fails to meet operational expectations—such as subject enrollment, protocol adherence, or data quality—it often foreshadows deeper issues in Good Clinical Practice (GCP) compliance. Regulators like the FDA, EMA, MHRA, and others use both performance indicators and inspection findings to assess whether a site or sponsor is consistently meeting obligations under ICH E6(R2).
Click to read the full article.

Historical Performance Review, Study Feasibility and Site Selection

Using EDC and CTMS Data for Site Review

Posted on digi By digi

In today’s clinical research environment, subjective feasibility questionnaires and anecdotal feedback are no longer sufficient to evaluate investigator site performance. Sponsors and CROs increasingly rely on structured, real-time data sources—most notably, Electronic Data Capture (EDC) systems and Clinical Trial Management Systems (CTMS)—to assess a site’s operational efficiency, compliance history, and future suitability for study participation.
Click to read the full article.

Historical Performance Review, Study Feasibility and Site Selection

Risk Scoring Based on Historical Site Metrics

Posted on digi By digi

Site selection in clinical trials has traditionally relied on feasibility questionnaires, investigator self-reporting, and sponsor relationships. However, this approach often overlooks objective indicators of operational risk—leading to poor enrollment, data quality concerns, and regulatory issues. Risk scoring based on historical site metrics enables sponsors and CROs to assign quantitative risk levels to each site, guiding feasibility, oversight intensity, and regulatory preparedness.
Click to read the full article.

Historical Performance Review, Study Feasibility and Site Selection

Importance of Location in Site Selection

Posted on digi By digi

Site location is a foundational pillar of clinical trial success. The geographic positioning of an investigator site influences patient accessibility, enrollment velocity, compliance with local regulations, infrastructure availability, and cost of operations. In today’s globalized research ecosystem, selecting the right site in the right place is not merely a logistical task—it is a strategic decision with direct implications on data quality, trial timelines, and regulatory acceptability.
Click to read the full article.

Geographic and Demographic Considerations, Study Feasibility and Site Selection

Demographic Suitability for Patient Recruitment

Posted on digi By digi

Recruiting the right patients for clinical trials requires more than protocol alignment and investigator capability—it depends critically on whether the site’s surrounding population matches the trial’s target demographic. Demographic suitability is a cornerstone of feasibility planning. Sponsors must ensure that selected sites are embedded in communities that reflect the inclusion and exclusion criteria of the protocol in terms of age, gender, ethnicity, comorbidities, education level, and socioeconomic status.
Click to read the full article.

Geographic and Demographic Considerations, Study Feasibility and Site Selection